Last reviewed · How we verify
Melperone HCl
At a glance
| Generic name | Melperone HCl |
|---|---|
| Sponsor | Lundbeck LLC |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Antipsychotic Induced Structural and Functional Brain Changes (PHASE4)
- Pharmacovigilance in Gerontopsychiatric Patients (PHASE3)
- Investigation of the Safety, Tolerability and Potential Therapeutic Effects of JNJ-40411813 in Patients With Schizophrenia (PHASE2)
- Melperone (an Anti-Psychotic) in Patients With Psychosis Associated With Parkinson's Disease (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Melperone HCl CI brief — competitive landscape report
- Melperone HCl updates RSS · CI watch RSS
- Lundbeck LLC portfolio CI